ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study

Investors Seem Wary Of Its Prospects, However

 
• By Leah Samuel
  
Desperate businessmen
RTB101 failed first trial, second trial stopped • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D